Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Check market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,915,307

« Back to Dashboard
Patent 7,915,307 protects SILENOR and is included in one NDA. There has been one Paragraph IV challenge on Silenor. There are two tentative approvals for the compound protected by this patent. Additional details are available via the generic ingredient links below.

This patent has two patent family members in two countries.

Summary for Patent: 7,915,307

Title:Methods of improving the pharmacokinetics of doxepin
Abstract:Methods of improving the pharmacokinetics of doxepin in a patient.
Inventor(s): Casseday; Cara Baron (San Diego, CA), Ludington; Elizabeth (San Diego, CA), Skinner; Michael (San Diego, CA), Dube; Susan (Carlsbad, CA), Rogowski; Roberta L. (Rancho Santa Fe, CA), Jochelson; Philip (San Diego, CA), Mansbach; Robert (San Diego, CA)
Assignee: Somaxon Pharmaceuticals, Inc. (San Diego, CA)
Application Number:11/781,165
Patent Claim Types:
see list of patent claims
Use; Dosage form;
Patent Metrics:
Source: PatentQuant.com
Field: Pharmaceuticals
Back Citations: 20th percentile
Forward Citations: 2nd percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Pernix Theraps Llc
doxepin hydrochloride
TABLET;ORAL022036-001Mar 17, 2010RXYesNo7,915,307► subscribe TREATMENT OF INSOMNIA
Pernix Theraps Llc
doxepin hydrochloride
TABLET;ORAL022036-002Mar 17, 2010RXYesYes7,915,307► subscribe TREATMENT OF INSOMNIA
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,915,307

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada2693992► subscribe
World Intellectual Property Organization (WIPO)2008011150► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.